Translating Genomics to Practice to Overcome Disparities in DLBCL
Official title: Project 2: Translating Genomics to Practice to Overcome Disparities in Diffuse Large B-Cell Lymphoma (DLBCL)
Funded at University of Tx Md Anderson Can Ctr · NIH-11401446 · Data updated 2026-11-12
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 22, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $492,085 |
| NIH project number | 5U54CA302435-02 |
| Project ID | NIH-11401446 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with diffuse large B-cell lymphoma who are willing to provide tumor samples and participate in genomic analyses or related studies.
✕Less likely to help
Patients not eligible for genomic testing or with conditions outside DLBCL may not directly benefit.
What this research studies
This initiative will study DLBCL by analyzing RNA and whole-exome sequencing from large patient groups that reflect the US population, and will grow a library of patient-derived tumor models to test new therapies. It also plans to compare existing molecular risk tools across all patients and explore strategies to improve trial enrollment that uses genomic information. The work involves collaboration with community clinics and biorepositories to ensure broad representation and real-world relevance. Results could help tailor treatments and improve access to trials for underserved patients.
Why it matters
Potential benefit: If successful, patients with DLBCL could receive more precise prognosis and better-matched therapies, including greater access to genomic-guided trials.
How similar studies have gone: Previous work shows that integrating genomic data with clinical care can improve risk stratification and guide targeted therapies in lymphoma, though disparities remain a challenge.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Flowers, Christopher R — University of Tx Md Anderson Can Ctr
- Study coordinator: Flowers, Christopher R
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
-
EBV-related lymphoma in people with immune deficiency: understanding what drives the disease
A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.